Indoco Remedies Ltd (BOM:532612)

Q3 2026 Indoco Remedies Ltd Earnings Call Transcript

Feb 03, 2026 / 10:00AM GMT

Release Date Price: ₹234.9 (+11.01%)

Transcript

Key Points

Positve

Indoco Remedies Ltd (BOM:532612) reported a strong performance in its exports division and API business, with significant growth in international markets.
The company launched two new products in the OTC segment in India, expanding its product portfolio and entering the clean toothpaste market.
Indoco Remedies Ltd (BOM:532612) received the EIR for its Patal Ganga API site from the USFDA, indicating compliance with regulatory standards.
The company achieved a rank improvement in the prescription audit, now ranked 21st, surpassing Pfizer, which is a significant achievement.
The FPP business in the US and Warren Remedies showed improved performance, contributing positively to the company's overall results.

Negative

The domestic business remained flat due to challenges in the acute therapies segment, impacting overall growth.
There were delays in approvals and customer-related issues in Europe, affecting expected growth in that region.
The company incurred one-time costs and penalties related to remediation and unsupplied products, impacting financial performance.
The US FDA warning letter for Goa Plant 2 continues to pose challenges, affecting the company's ability to fully capitalize on its product portfolio.
High competition in the cardio-diabetes segment limits growth opportunities, as Indoco Remedies Ltd (BOM:532612) focuses on other therapeutic areas.

Operator

Ladies and gentlemen, good day and welcome to Indico Remedies Limited Q3 FY'26 earnings conference called (Hoseed Vander Bank Equities Institution). (Operators Instructions)

I now have the conference over to Mr. Umesh Rahada from Nirmal Bank Equities Institution.

Thank you and over to you, sir.

Umesh Rahada

Nirmal Bank Equities Institution - Analyst

Hello, I'm audible.

Operator

Yes, sir.

Umesh Rahada

Nirmal Bank Equities Institution - Analyst

So good afternoon, everyone.

I am Umesh Rahada from Nirmal Bank Institutional Equities. It gives me immense pleasure to hold 3Q FY'I26 Indoor Remedies Limited con call. From the management we have Ms. Aditi Panandikar, Managing Director, Mr. Sundeep Bambolkar, Joint MD, and Mr. Pramod Ghorpade, CFO.

Now I pass it over to the management for their opening remarks.

Pramod Ghorpade

Indoco Remedies Ltd - Chief Financial Officer

Thank you. Good afternoon,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.